Detalles de la búsqueda
1.
The genomic landscape of response to EGFR blockade in colorectal cancer.
Nature
; 526(7572): 263-7, 2015 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26416732
2.
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Breast Cancer Res
; 22(1): 48, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32414394
3.
Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
J Pharmacokinet Pharmacodyn
; 47(1): 5-18, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31679083
4.
Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.
Int J Cancer
; 143(1): 151-159, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29435981
5.
Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
J Neurooncol
; 138(3): 489-498, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564747
6.
Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Int J Cancer
; 139(9): 2095-105, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27342948
7.
Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation.
Sci Rep
; 10(1): 663, 2020 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31959764
8.
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.
Sci Transl Med
; 12(555)2020 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32759276
9.
CD4+ and CD8a+ PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
Theranostics
; 9(26): 8221-8238, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31754392
10.
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
MAbs
; 11(4): 666-680, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31046547
11.
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Mol Cancer Ther
; 18(11): 2135-2145, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31484705
12.
Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015.
Mol Cancer Ther
; 17(6): 1259-1270, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29545332
13.
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 4(4): e175245, 2018 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29423521
14.
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
J Natl Cancer Inst
; 109(11)2017 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29059433
15.
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.
Clin Cancer Res
; 23(19): 5923-5935, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28679766
16.
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.
Mol Cancer Ther
; 16(12): 2780-2791, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28802255
17.
Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma.
Cancer Res
; 62(4): 1191-5, 2002 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11861403
18.
Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.
Mol Cancer Ther
; 15(7): 1614-26, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27196767
19.
Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models.
Clin Cancer Res
; 22(3): 633-43, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26420857
20.
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Clin Cancer Res
; 22(13): 3260-7, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26888827